Description
A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (APHINITY)
This randomized, double-blind, placebo-controlled, two-arm study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus trastuzumab as adjuvant therapy in participants with operable HER2-positive primary breast cancer. This study will be carried out in collaboration with the Breast International Group (BIG).
Location: SIMR (Sacramento/Valley Area)
Please contact: SIMR@sutterhealth.org about APHINITY
Principal Investigator
Related Studies
Breast Cancer Chemoprevention in Primary Care at Geisinger
Identify PCPs’ awareness of breast cancer risk assessment and breast cancer chemoprevention knowledge, and identify perceived barriers and clinic solutions.
Investigators: Xiaowei (Sherry) Yan, PhD, MS, External PI, Principal Investigator